Tempest Therapeutics (TPST) Assets Average (2012 - 2026)
Tempest Therapeutics (TPST) posted Assets Average of $17.0 million for Q4 2025, down 18.15% sequentially from $20.8 million in Q3 2025, and down 54.78% YoY from $37.7 million in Q4 2024.
Tempest Therapeutics (TPST) Assets Average (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Assets Average for 14 years, with the latest figure at $17.0 million in Q4 2025.
- Quarterly Assets Average fell 54.78% year-over-year to $17.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.0 million (down 54.78% YoY) and the FY2025 annual result came in at $29.2 million, down 37.25% from the prior year.
- Assets Average eased to $17.0 million in Q4 2025 per TPST's latest filing, from $20.8 million in the prior quarter.
- Over five years, Assets Average peaked at $74.4 million in Q2 2021 and troughed at $17.0 million in Q4 2025.
- A 5-year average of $46.8 million and a median of $42.5 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2021 and 2023: Assets Average jumped 207.0% in 2021, then tumbled 59.32% in 2023.
- Over 5 years, Assets Average stood at $70.2 million in 2021, then retreated by 22.17% to $54.6 million in 2022, then plunged by 30.82% to $37.8 million in 2023, then fell by 0.35% to $37.7 million in 2024, then slumped by 54.78% to $17.0 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $17.0 million, $20.8 million, and $28.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | 13.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.28 Mn |
| Dec 31, 2025 | 17.03 Mn |
| Sep 30, 2025 | 20.81 Mn |
| Jun 30, 2025 | 28.32 Mn |
| Mar 31, 2025 | 36.83 Mn |
| Dec 31, 2024 | 37.66 Mn |
| Sep 30, 2024 | 38.00 Mn |
| Jun 30, 2024 | 43.27 Mn |
| Mar 31, 2024 | 47.99 Mn |
| Dec 31, 2023 | 37.80 Mn |
| Sep 30, 2023 | 27.36 Mn |
| Jun 30, 2023 | 34.04 Mn |
| Mar 31, 2023 | 41.71 Mn |
| Dec 31, 2022 | 54.63 Mn |
| Sep 30, 2022 | 67.26 Mn |
| Jun 30, 2022 | 69.15 Mn |
| Mar 31, 2022 | 70.10 Mn |
| Dec 31, 2021 | 70.19 Mn |
| Sep 30, 2021 | 71.32 Mn |
| Jun 30, 2021 | 74.37 Mn |